Jump to main content
Research Type: Reports
-
Xeljanz, the FDA, and nine years of patient harm
Read More
-
Atypical antipsychotics: Decades of use, unfathomable harms
Read More
-
Medicare Part B Premium Dynamics Explained
Read More
-
Comparing Factors that Influence Pharmaceutical Pricing and Access in the US and five other Countries
Read More
-
Biosimilars in Medicare Part D: pricing dynamics and considerations
Read More
-
Evaluating Industry’s Drug Pricing Claims
Read More
-
Production Plus Profit Pricing (P-quad) FAQ
Read More
-
Biosimilars: Market Changes do not equal policy success
Read More
-
Ethics of Clinical Trials to Evaluate Biosimilars
Read More
-
Bottom-Up Pricing Estimate for P-quad
Read More